Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Boehringer Ingelheim enters €410m licence deal with Kyowa Kirin Co., Ltd.
Under the terms of a new licencing and co-development deal, Boehringer Ingelheim will receive the exclusive, worldwide rights from Kyowa Kirin to...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Under the term of the agreement, Redx Pharma plc (Alderley Park, UK) is to receive US$10m upfront and up to US$870m in milestone payments. Redx is...
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...